You just read:

Novartis presents results from four pivotal Phase III studies for investigational drug secukinumab (AIN457) in psoriatic arthritis and ankylosing spondylitis at ACR 2014

News provided by

Novartis Pharmaceuticals Canada Inc.

Nov 17, 2014, 08:00 ET